open-label trial designed to determine whether lowering low-density lipoprotein cholesterol with the HMG-CoA-reductase inhibitor pravastatin reduced all-cause mortality compared to a control group ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

In an analysis of health data from 130million people, British researchers found medications which could potentially increase, ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

(2) You are limited to two withdrawals a year or the rate drops (3) You are limited to three withdrawals a year or the rate drops (4) You are limited to four withdrawals a year or the rate drops ...